Overview

A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To compare the time to progression of Cytomegalovirus (CMV) retinitis among each of three doses of oral ganciclovir, as well as to intravenous therapy, when given as maintenance for 26 weeks. To compare the safety and tolerance among oral doses of ganciclovir at the study doses, as well as to intravenous therapy, when administered as maintenance for 26 weeks.
Phase:
N/A
Details
Lead Sponsor:
Roche Global Development
Treatments:
Ganciclovir
Ganciclovir triphosphate